DexCom Inc (DXCM)
390.26
-15.32 (-3.78%)
USD |
NASDAQ |
Mar 11, 16:00
391.00
+0.74 (+0.19%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 37.88B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 6.40% |
| Valuation | |
| PE Ratio | 251.78 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 15.96 |
| Price to Book Value | 16.82 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.7563 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 56.37% |
News
Headline
Wire
Time (ET)
Yahoo
03/07 06:00
Yahoo
02/28 06:00
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 04/29/2022* | -- | Results | Q1 2022 | -- | 0.54 | -- | |
| 04/29/2022* | 16:30 EST | Earnings Call | Q1 2022 | -- | -- | -- | |
| 02/10/2022 | -- | Results | Q4 2021 | 0.68 | 0.85 | -19.90% | |
| 02/10/2022 | 16:30 EST | Earnings Call | Q4 2021 | -- | -- | -- | |
| 10/28/2021 | -- | Results | Q3 2021 | 0.89 | 0.65 | 37.81% | |
| 10/28/2021 | 16:30 EST | Earnings Call | Q3 2021 | -- | -- | -- | |
| 07/29/2021 | -- | Results | Q2 2021 | 0.76 | 0.44 | 71.05% | |
| 07/29/2021 | 16:30 EST | Earnings Call | Q2 2021 | -- | -- | -- |
*Estimated Date/Time
Earnings
Profile
Edit
| Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver. |
| URL | https://www.dexcom.com |
| Investor Relations URL | https://investors.dexcom.com |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Medical Devices |
| Equity Style | Large Cap/Growth |
| Next Earnings Release | Apr. 29, 2022 (est.) |
| Last Earnings Release | Feb. 10, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0.00% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Edit comparables
Annual Total Returns Versus Peers
Edit comparables
As of March 11, 2022.
Fundamentals
| Revenue (TTM) | 2.448B |
| Total Expenses (TTM) | 2.183B |
| Net Income (TTM) | 154.70M |
| Total Assets (Quarterly) | 4.864B |
| Total Liabilities (Quarterly) | 2.612B |
| Shareholders Equity (Quarterly) | 2.252B |
| Cash from Operations (TTM) | 442.50M |
| Cash from Investing (TTM) | -216.10M |
| Cash from Financing (TTM) | 10.40M |
Ratings
Profile
Edit
| Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver. |
| URL | https://www.dexcom.com |
| Investor Relations URL | https://investors.dexcom.com |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Medical Devices |
| Equity Style | Large Cap/Growth |
| Next Earnings Release | Apr. 29, 2022 (est.) |
| Last Earnings Release | Feb. 10, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Top Fund Holders
| Symbol | Dollars Invested | % Weight |
|---|---|---|
| IHI | 251.57M USD | 3.30% |
| WMGBX | 233.09M USD | 3.21% |
| FSMEX | 264.75M USD | 2.91% |
| RPG | 54.40M USD | 2.19% |
| JDCRX | 453.15M USD | 2.01% |
| LGLUX | 165.55M USD | 1.76% |
| NUGO | 56.82M USD | 1.73% |
| VMGIX | 276.78M USD | 1.24% |
| VOT | 276.78M USD | 1.24% |
| IWP | 149.87M USD | 1.17% |
| VIMSX | 943.33M USD | 0.60% |
| VO | 943.33M USD | 0.60% |
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Morningstar | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| Stocktwits | DXCM Tweets |